BD&L Diligence Dossier
30-second diligence on any drug or target: biology, clinical stage, safety, patents, funding, literature, and revenue signals.
The problem this solves
Life sciences teams need decisions faster than public data can be cleaned manually. This solution compresses months of preparation into a governed, query-ready product.
VP-level and director-level teams often know which questions matter, but the required data is spread across incompatible FDA, CMS, NIH, EMA, USPTO, literature, ontology, and identity sources.
BD&L Diligence Dossier removes the repeated engineering work by delivering the connected tables, bridge keys, and sample queries that your team would otherwise build from scratch.
What you get
Asset and target evidence cards that combine mechanism, clinical phase, target-disease score, and literature momentum.
Competitive trial landscape, sponsor normalization, patent runway, and safety signal summaries in the same schema.
NIH funding, publication, and disease ontology context for external innovation and indication strategy.
Query-ready diligence outputs for BD, search-and-evaluation, and corporate strategy workflows.
Data Products Powering This Solution
Each card links to a query-ready data product in the biomedical estate.
Drug-Target Bioactivity Intelligence (ChEMBL)
2.5M compounds • Quarterly
ScientificProtein Target Intelligence (Swiss-Prot)
20,370 human proteins • Quarterly
Disease & OntologyOpen Targets Platform Intelligence
7.5M target-disease associations • Quarterly
ClinicalClinical Trial Intelligence (ClinicalTrials.gov)
519K+ trials • Weekly
IP & PatentFDA Orange Book Patent Intelligence
15K+ patents • Monthly
IP & PatentUSPTO Patent Intelligence
8M+ patents • Quarterly
RegulatoryFDA Adverse Event Signal Intelligence (FAERS)
25M+ reports • Quarterly
ClinicalNIH Research Funding Intelligence
1.27M grants • Annual
LiteraturePubMed Biomedical Literature Intelligence
10.2M papers • Monthly
ClinicalEMA European Drug Authorization Intelligence
1,500+ products • Monthly
Disease & OntologyMONDO Disease Ontology Intelligence
25K+ terms • Quarterly
Day-one query results for KRAS G12C
Designed sample output showing the type of redacted table your analysts can query immediately after provisioning.
| Signal | Value | Source |
|---|---|---|
| Canonical entity | KRAS G12C | Drug spine |
| Primary risk score | High confidence | Pre-computed model |
| Connected products | 11 products | TDD catalog |
| Latest refresh | 2026-09-01 | Lineage table |
Built for the teams who own the decision
For BD&L teams
Screen target or asset opportunities before deep diligence starts and prioritize the highest-signal assets.
For Search and evaluation teams
Compare mechanisms, trial progress, funding intensity, safety burden, and IP runway across targets.
For Corporate strategy teams
Build thematic landscapes around diseases, modalities, platforms, and external innovation clusters.
Common questions
Procurement, architecture, and analytics teams can evaluate exactly how the product will land in your environment.
Query on day one
Sample SQL included
Is the dossier generated from public data only?
Yes. It uses public biomedical authorities and does not require proprietary, patient-level, or confidential data.
Can we customize the scoring weights?
Yes. Core tables are delivered query-ready, and customers can adjust prioritization logic inside their own warehouse.
Does it include target biology?
Yes. ChEMBL, UniProt, Open Targets, disease ontology, publications, and funding data are connected through target and disease identifiers.
See This Solution In Action
We'll walk through live warehouse queries and sample outputs for your specific use case.
Request Demo